Graft versus host disease (GvHD) is one of the most feared adverse events of allogeneic
hematopoietic stem cell transplantation. In severe grades of GvHD patients die from …

Background: Chronic cutaneous graft-versus-host disease (GvHD) can arise as a late
complication after allogeneic bone marrow transplantation. Patients with extensive disease …

Chronic graft-versus-host disease (cGVHD) is a major limitation of successful hematopoietic
cell transplantation. The safety and efficacy of extracorporeal photopheresis (ECP) for 12 to …

Figure 1 Photo documentation of a 49-year-old female patient prior to ECP (a1–a3), at the
time of the initial objective response after 32 months (36 cycles of ECP; b1–b3) and after 58 …

Extracorporeal photochemotherapy (ECP; photopheresis), an immunomodulatory therapy,
has previously demonstrated promising results in treating chronic graft-versus-host disease …

Abstract Extracorporeal photochemotherapy (ECP; photopheresis), an immunomodulatory
therapy developed for cutaneous T‐cell lymphoma, has shown promise in treating chronic …

Background. Graft-versus-host disease (GVHD) is a major complication after bone marrow
transplantation, which may be refractory to immunosuppressive drugs. As preliminary case …

We enrolled 25 patients with extensive, steroid-refractory chronic graft-versus-host disease
(cGVHD) in a prospective trial evaluating the efficacy of extracorporeal photophoresis (ECP) …

The aim of our study was to assess the efficacy of extracorporeal photopheresis (ECP) in
chronic graft-versus-host disease (GVHD). Eleven patients with chronic cutaneous GVHD …

In a prior multicenter randomized controlled trial, we found that a 12-week course of
extracorporeal photopheresis (ECP) plus standard immunosuppressive therapy resulted in …